155 related articles for article (PubMed ID: 22481019)
1. LASP-1, a novel urinary marker for detection of bladder cancer.
Ardelt P; Grünemay N; Strehl A; Jilg C; Miernik A; Kneitz B; Butt E
Urol Oncol; 2013 Nov; 31(8):1591-8. PubMed ID: 22481019
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
3. Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma.
Butt E; Ebbing J; Bubendorf L; Ardelt P
Biomark Med; 2017 Apr; 11(4):347-357. PubMed ID: 28290211
[TBL] [Abstract][Full Text] [Related]
4. LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma.
Wang H; Li W; Jin X; Cui S; Zhao L
Eur J Cancer; 2013 Mar; 49(4):974-83. PubMed ID: 23084841
[TBL] [Abstract][Full Text] [Related]
5. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
6. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
7. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
9. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
11. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation.
Grunewald TG; Kammerer U; Winkler C; Schindler D; Sickmann A; Honig A; Butt E
Br J Cancer; 2007 Jan; 96(2):296-305. PubMed ID: 17211471
[TBL] [Abstract][Full Text] [Related]
16. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1.
Zhao L; Wang H; Liu C; Liu Y; Wang X; Wang S; Sun X; Li J; Deng Y; Jiang Y; Ding Y
Gut; 2010 Sep; 59(9):1226-35. PubMed ID: 20660701
[TBL] [Abstract][Full Text] [Related]
17. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
18. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
[TBL] [Abstract][Full Text] [Related]
19. LIM and SH3 domain protein 1 (LASP-1) overexpression was associated with aggressive phenotype and poor prognosis in clear cell renal cell cancer.
Yang F; Zhou X; Du S; Zhao Y; Ren W; Deng Q; Wang F; Yuan J
PLoS One; 2014; 9(6):e100557. PubMed ID: 24955835
[TBL] [Abstract][Full Text] [Related]
20. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
